Future of inflammatory bowel disease treatment: A review of novel treatments beyond guidelines

Table 1 Distinction between biologics vs small molecules in inflammatory bowel disease

Feature	Biologics	Small molecules
Route of administration	IV-Subcutaneous	Oral
Risk of immunogenicity	High	Low
Onset of action	Moderate to slow	Fast
Long-term safety	Documented	Low data
Cost	Variable	High
Combination use	Immunomodulators	Biologics (some)